1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends
  4. > Growth Hormone (GH) Agonists -Pipeline Insights, 2016

Growth Hormone (GH) Agonists -Pipeline Insights, 2016

  • November 2016
  • -
  • Delve Insight
  • -
  • 60 pages


DelveInsight’s, “Growth Hormone (GH) Agonists-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Growth Hormone (GH) Agonists. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Growth Hormone (GH) Agonists. DelveInsight’s Report also assesses the Growth Hormone (GH) Agonists therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitive pipeline landscape of Growth Hormone (GH) Agonists
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Growth Hormone (GH) Agonists pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Growth Hormone (GH) Agonists and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Growth Hormone (GH) Agonists -Pipeline Insights, 2016

- Growth Hormone (GH) Agonists Overview
- Growth Hormone (GH) Agonists Disease Associated
- Growth Hormone (GH) Agonists Pipeline Therapeutics
- Growth Hormone (GH) Agonists Therapeutics under Development by Companies
- Growth Hormone (GH) Agonists Filed and Phase III Products
- Comparative Analysis
- Growth Hormone (GH) Agonists Phase II Products
- Comparative Analysis
- Growth Hormone (GH) Agonists Phase I and IND Filed Products
- Comparative Analysis
- Growth Hormone (GH) Agonists Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Growth Hormone (GH) Agonists - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Growth Hormone (GH) Agonists - Discontinued Products
- Growth Hormone (GH) Agonists - Dormant Products
- Companies Involved in Therapeutics Development for Growth Hormone (GH) Agonists
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for Growth Hormone (GH) Agonists by Therapy Area, 2016
- Number of Products under Development for Growth Hormone (GH) Agonists, 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- Growth Hormone (GH) Agonists Assessment by Monotherapy Products
- Growth Hormone (GH) Agonists Assessment by Combination Products
- Growth Hormone (GH) Agonists Assessment by Route of Administration
- Growth Hormone (GH) Agonists Assessment by Stage and Route of Administration
- Growth Hormone (GH) Agonists Assessment by Molecule Type
- Growth Hormone (GH) Agonists Assessment by Stage and Molecule Type
- Growth Hormone (GH) Agonists Therapeutics - Discontinued Products
- Growth Hormone (GH) Agonists Therapeutics - Dormant Products
- Products under Development by Companies, 2016

List of Figures

- Number of Products under Development for Growth Hormone (GH) Agonists by Therapy Area, 2016
- Number of Products under Development for Growth Hormone (GH) Agonists, 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- Growth Hormone (GH) Agonists Assessment by Monotherapy Products
- Growth Hormone (GH) Agonists Assessment by Combination Products
- Growth Hormone (GH) Agonists Assessment by Route of Administration
- Growth Hormone (GH) Agonists Assessment by Stage and Route of Administration
- Growth Hormone (GH) Agonists Assessment by Molecule Type
- Growth Hormone (GH) Agonists Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Growth Hormone Deficiency (GHD)  - Market Insights, Epidemiology and Market Forecast-2023

Growth Hormone Deficiency (GHD)  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Growth Hormone Deficiency (GHD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Growth Hormone Deficiency ...

Growth Hormone Deficiency (GHD)  - Epidemiology Forecast To 2023

Growth Hormone Deficiency (GHD)  - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight “Growth Hormone Deficiency (GHD)  - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Growth Hormone Deficiency (GHD)  in seven major markets (US, France, ...

Growth Hormone Deficiency-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Growth Hormone Deficiency-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

  • $ 2000
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Report, “Growth Hormone Deficiency-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.